Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Explore this paper's citation graph
Summary
Results are in accord with two previous trials with different pharmacologic agents and indicate that modification of lipoprotein levels with gemfibrozil reduces the incidence of coronary heart disease in men with dyslipidemia.
- Type
- article
- Published
- 1987-11-12
- Cited by
- 3,802
- References
- 41
- OpenAlex
- https://openalex.org/W2341665659
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32319998
Keywords
Gemfibrozil, Dyslipidemia, Medicine, Placebo, Internal medicine
References
- The Framingham Study: The Epidemiology of Atherosclerotic Disease
- Seven countries. A multivariate analysis of death and coronary heart disease.
- Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study.
- The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study.
- Value, sensitivity and specificity of stroke volume ratio in routine equilibrium gated scintigraphy.
- Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men.
- Discrete sequential boundaries for clinical trials
- Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.
- Progression of coronary artery disease in randomized medical and surgical patients over a 5-year angiographic follow-up.
- Mechanism of action of gemfibrozil on lipoprotein metabolism.
- A short rating scale as a potential measure of pattern A behavior.
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.
- Incubation period of coronary heart disease.
- Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.
- Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects.
- Clinical results with gemfibrozil and background to the Helsinki Heart Study.
- Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study.
- The Electrocardiogram in Population Studies: A Classification System
- A multiple testing procedure for clinical trials.
- The pathogenesis of atherosclerosis--an update.
Cited by
- Screening for hypercholesterolemia in children: the missing links.
- Race and gender differences in serum lipoproteins of children, adolescents, and young adults--emergence of an adverse lipoprotein pattern in white males: the Bogalusa Heart Study.
- Medication compliance and serum lipid changes in the Helsinki Heart Study.
- Workshop VI--Regression of atherosclerosis: what does it mean?
- Hyperlipidemia after cardiac transplantation: be aware and possibly wary of drug therapy for lowering of serum lipids.
- Prevention and regression of atherosclerosis with drug therapy
- Kidney function and cardiovascular risk factors in non‐insulin‐dependent diabetics (NIDDM) with microalbuminuria
- Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study.
- Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data.
- Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels.
- Fish oil and plasma fibrinogen.
- Fenofibrate-Induced Hyperhomocysteinaemia
- Managing the Patient with Hypertriglyceridemia: A Practical Approach for Nurse Practitioners
- Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia.
- Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
- Lipid-lowering effect and safety of acipimox in hemodialysis patients and renal transplant recipients.
- The effects of lowering serum cholesterol on coronary heart disease risk.
- Effect of Gemfibrozil on Fatty Acids in Lipid Fractions of Plasma From Patients with Hypertriglyceridemia
- Delayed Progression or Regression of Coronary Atherosclerosis with Intensive Risk Factor Modification
- Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment
Related papers
- INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL
- Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
- [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
- [Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients].
- Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas)
- Gemfibrozil as a Lipid Lowering Compound in Hyperlipoproteinæmia. A Placebo-controlled Cross-over Trial
- Apparent Reduced Absorption of Gemfibrozil When Given with Colestipol
- Novel Association between Gemfibrozil and Dyslipidemia: A Case Report